<DOC>
	<DOCNO>NCT00291759</DOCNO>
	<brief_summary>The purpose study assess difference event-free survival postmenopausal woman hormone receptor-positive early breast cancer switch tamoxifen anastrozole continue receive tamoxifen .</brief_summary>
	<brief_title>ABCSG 8 - Adjuvant Treatment Patients With Hormone Receptor-positive Breast Cancer With Good Moderate Differentiation .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Invasive mammary carcinoma radical treatment , without prior chemo/hormone/radiation therapy . At least 6 lymph node examine . Good intermediate tumour differentiation . &lt; 6 week start adjuvant therapy . Oestrogen Progesterone positive Premenopausal . Preoperative hormonal/antihormonal/radiation/cytoxic chemo . Second malignant tumour/status post second malignant tumour . Insitu/T4 carcinoma . Age &gt; 80 year . World Health Organisation performance index &gt; 3 . Serious accompany disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>